7th CB1, CB2 and Cannabinoid Drug Development Summit

As drug developers continue to utilize the expedited FDA regulatory pathway available for CBD, alongside a growing interest in the therapeutic benefits and regulatory approval of novel cannabinoids, the cannabinoid drug development landscape is rapidly evolving. Additionally, innovative preclinical candidates targeting CB1 and CB2 receptors are advancing through the pipeline, as developers aim to secure regulatory approval for treatments addressing weight management, pain, neurological conditions, and more.

The field continues to grow, with both phytocannabinoid and synthetic drug candidates aspiring to achieve milestones like those set by Epidiolex, Marinol, Syndros, and Cesamet.

Join 60+ experts from discovery, preclinical, translational, regulatory, clinical, and chemistry fields at the 7th CB1, CB2, and Cannabinoid Drug Development Summit as they work to unlock the potential of CB1, CB2, and cannabinoid drugs for treating obesity, pain, inflammation, CNS disorders, and rare diseases.

URLs:
Website: https://go.evvnt.com/2621613-0?pid=10018
Tickets: https://go.evvnt.com/2621613-1?pid=10018
Brochure: https://go.evvnt.com/2621613-3?pid=10018

Prices:
Drug Developer Pricing - Conference + 2 Workshops: USD 3497.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3048.00,
Drug Developer Pricing - Conference Only: USD 2599.00,
Academic Pricing - Conference + 2 Workshops: USD 2897.00,
Academic Pricing - Conference + 1 Workshop: USD 2548.00,
Academic Pricing - Conference Only: USD 2199.00,
Solution Provider - Conference + 2 Workshops: USD 4397.00,
Solution Provider - Conference + 1 Workshop: USD 3848.00,
Solution Provider - Conference Only: USD 3299.00

Speakers: Akeem Gardner, CEO and Founder, Canurta, Alexandros Makriyannis, Director, Center for Drug Discovery, Northeastern University, Andrea Chicca, Chief Executive Officer, Synendos Therapeutics, Andrea Small-Howard, Chief Executive Officer, GB Sciences, Arnold Lippa, CEO and CSO, RespireRx Pharmaceuticals Inc, Dean Petkanas, Chief Executive Officer, Neuropathix, George Kunos, Senior Investigator, Laboratory of Physiologic Studies; Section of Neuroendocrinology, National Institute on Alcohol Abuse and Alcoholism - NIAAA, Heather Krug, Regulatory Programs Branch Chief, Colorado Department of Public Health and Environment, Hunter Land, Vice President, Research and Development, Biopharmaceutical Research Co., Jacci (Jacquelyn) Bainbridge Professor, Vice Chair, Department of Clinical Pharmacy, Anschutz Outpatient Pavilion, University of Colorado Denver | Anschutz Medical Campus, Jeff Margolis ,SVP, CFO, Treasurer, Secretary, RespireRx Pharmaceuticals Inc, Jennifer Triemstra, Associate Medical Director, Jazz Pharmaceuticals Inc, Joseph Foss, Chief Medical Officer, NeuroTherapia Inc, Kamaluddin Abdur-Rashid, Co-Founder, President and Chief Technology Officer, Kare Chemical Technologies Inc, Mary Ellen Johnson, Global Director Business Development, DSM, Michael Palfreyman, Senior Advisor - Research and Development, Cybin Inc, Parveen Bhatarah, Founder, Medcann Ltd., Paul Gavin, Chief Executive Officer, Avecho Biotechnology, Saoirse O’Sullivan, Vice President of Translational Research, Artelo Biosciences, Terry O’Regan, President, Brains Bioceutical Corp., Uwe Grether, Expert Scientist, Roche